Krystal Biotech, Inc. - 8-K Filing

Krystal Biotech reports Q2 2026 VYJUVEK global revenue of $119.2M and ends quarter with $1.1B in cash (Items: 2.02 Results of Operations and Financial ConditionOn August 3, 2026, Krystal Biotech, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KRYS

Read the full article at SEC EDGAR

More Regulatory news